Chemours (NYSE:CC) Stock Price Down 6.4% - Time to Sell?

The Chemours Company (NYSE:CC - Get Free Report) traded down 6.4% during mid-day trading on Monday . The stock traded as low as $9.61 and last traded at $9.48. 432,605 shares were traded during mid-day trading, a decline of 80% from the average session volume of 2,137,567 shares. The stock had previously closed at $10.13.

Analyst Ratings Changes

Several equities analysts have issued reports on CC shares. BMO Capital Markets dropped their price objective on Chemours from $34.00 to $27.00 and set an "outperform" rating on the stock in a report on Wednesday, February 19th. UBS Group dropped their price target on Chemours from $18.00 to $17.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Morgan Stanley cut their price target on Chemours from $22.00 to $15.00 and set an "equal weight" rating on the stock in a research report on Monday, May 12th. Mizuho set a $15.00 price objective on Chemours in a research note on Tuesday, April 15th. Finally, Royal Bank of Canada lowered their target price on shares of Chemours from $17.00 to $14.00 and set an "outperform" rating on the stock in a research report on Thursday, May 8th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $17.22.

Chemours Trading Up 1.2%

The company has a 50 day simple moving average of $11.30 and a 200 day simple moving average of $15.49. The company has a current ratio of 1.68, a quick ratio of 0.92 and a debt-to-equity ratio of 6.70. The stock has a market capitalization of $1.50 billion, a PE ratio of 17.63 and a beta of 1.76.

Chemours (NYSE:CC - Get Free Report) last released its earnings results on Tuesday, May 6th. The specialty chemicals company reported $0.13 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.19 by ($0.06). Chemours had a net margin of 1.51% and a return on equity of 26.54%. The company had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.36 billion. During the same period in the previous year, the firm posted $0.32 EPS. The company's revenue for the quarter was up .4% on a year-over-year basis. Analysts predict that The Chemours Company will post 2.03 earnings per share for the current fiscal year.

Chemours Dividend Announcement

The company also recently disclosed a dividend, which will be paid on Monday, June 16th. Shareholders of record on Monday, May 19th will be paid a $0.0875 dividend. The ex-dividend date is Friday, May 16th. This represents a yield of 3.17%. Chemours's dividend payout ratio is currently 175.00%.

Insiders Place Their Bets

In other Chemours news, insider Damian Gumpel purchased 7,822 shares of Chemours stock in a transaction dated Tuesday, June 3rd. The stock was acquired at an average cost of $9.95 per share, with a total value of $77,828.90. Following the acquisition, the insider now directly owns 131,701 shares of the company's stock, valued at $1,310,424.95. This represents a 6.31% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Shane Hostetter acquired 4,450 shares of the company's stock in a transaction that occurred on Monday, May 19th. The shares were acquired at an average cost of $11.28 per share, for a total transaction of $50,196.00. Following the acquisition, the chief financial officer now directly owns 59,694 shares of the company's stock, valued at $673,348.32. This trade represents a 8.06% increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.47% of the stock is owned by insiders.

Institutional Investors Weigh In On Chemours

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Corient Private Wealth LLC grew its stake in shares of Chemours by 4.7% during the 4th quarter. Corient Private Wealth LLC now owns 13,428 shares of the specialty chemicals company's stock worth $227,000 after purchasing an additional 604 shares during the period. HUB Investment Partners LLC boosted its holdings in Chemours by 1.4% during the fourth quarter. HUB Investment Partners LLC now owns 58,250 shares of the specialty chemicals company's stock worth $984,000 after buying an additional 821 shares in the last quarter. UMB Bank n.a. grew its position in Chemours by 73.9% during the first quarter. UMB Bank n.a. now owns 2,231 shares of the specialty chemicals company's stock worth $30,000 after buying an additional 948 shares during the period. Itau Unibanco Holding S.A. grew its position in Chemours by 39.3% during the fourth quarter. Itau Unibanco Holding S.A. now owns 3,554 shares of the specialty chemicals company's stock worth $60,000 after buying an additional 1,003 shares during the period. Finally, ARGA Investment Management LP increased its holdings in Chemours by 0.7% in the fourth quarter. ARGA Investment Management LP now owns 148,614 shares of the specialty chemicals company's stock valued at $2,512,000 after buying an additional 1,032 shares in the last quarter. Institutional investors and hedge funds own 76.26% of the company's stock.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.